5 Best Growth ETFs To Buy Now

2. Schwab U.S. Large-Cap Growth ETF (NYSE:SCHG)

5-Year Share Price Performance as of March 27: 133.51%

Schwab U.S. Large-Cap Growth ETF (NYSE:SCHG)’s goal is to closely track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index, before fees and expenses. As of March 27, 2024, the fund’s net assets amounted to 26.8 billion and its expense ratio came in at 0.040%, and its portfolio consists of 249. Schwab U.S. Large-Cap Growth ETF (NYSE:SCHG) is one of the best growth ETFs to monitor. 

UnitedHealth Group Incorporated (NYSE:UNH) is one of the top holdings of Schwab U.S. Large-Cap Growth ETF (NYSE:SCHG). On January 12, UnitedHealth Group Incorporated (NYSE:UNH) reported a Q4 non-GAAP EPS of $6.16 and a revenue of $94.4 billion, outperforming Wall Street estimates by $0.17 and $2.22 billion, respectively. 

According to Insider Monkey’s fourth quarter database, 113 hedge funds were bullish on UnitedHealth Group Incorporated (NYSE:UNH), compared to 104 funds in the prior quarter. 

Sequoia Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its fourth quarter 2023 investor letter:

“The return in UnitedHealth Group Incorporated (NYSE:UNH) shares was essentially flat last year, whereas the Index was up sharply. In 2022, the return in UnitedHealth shares was modestly positive, whereas the Index was down sharply. The company’s financial performance, however, has been quite steady all along. In 2022, United’s revenues and earnings per share were up approximately 13% and 17%, respectively. We expect them both to be up low-teens in 2023. These pleasing financial results are consistent with United’s historical track record and with what we believe we will see for years to come.

Last year, sentiment across the managed care space was negatively impacted by concerns over reimbursement levels for Medicare Advantage, a perceived increase in the risk of adverse regulation for pharmacy benefit managers, and a slight deterioration of medical loss trends. While we do not dismiss these factors as irrelevant, we consider them in the context of the scale and diversity of United’s business as well as the resulting essential role the company plays in the admittedly imperfect US healthcare system…” (Click here to read the full text)